c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

Ovarian cancer is the most lethal gynecologic cancer mainly because of widespread peritoneal dissemination and malignant ascites. Key to this is the capacity of tumor cells to escape suspension-induced apoptosis (anoikis), which also underlies their resistance to chemotherapy. Here, we used a nonadherent cell culture model to investigate the molecular mechanisms of apoptotic resistance of ovarian cancer cells that may mimic the chemoresistance found in solid tumors. We found that ovarian cancer cells acquired a remarkable resistance to anoikis and apoptosis induced by exposure to clinically relevant doses of two front-line chemotherapeutic drugs cisplatin and paclitaxel when grown in three-dimensional than monolayer cultures. Inhibition of the hepatocyte growth factor (HGF) receptor c-Met, which is frequently overexpressed in ovarian cancer, by a specific inhibitor or small interfering RNA blocked the acquired anoikis resistance and restored chemosensitivity in three-dimensional not in two-dimensional cultures. These effects were found to be dependent on both phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) 1/2 signaling pathways. Inhibitors of PI3K/Akt abrogated ERK1/2 activation and its associated anoikis resistance in response to HGF, suggesting a signaling relay between these two pathways. Furthermore, we identified a central role of Ras as a mechanism of this cross talk. Interestingly, Ras did not lie upstream of PI3K/Akt, whereas PI3K/Akt signaling to ERK1/2 involved Ras. These findings shed new light on the apoptotic resistance mechanism of nonadherent ovarian cancer ascites cells and may have important clinical implications.

[1]  J. Nör,et al.  Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. , 2009, Neoplasia.

[2]  A. Scott,et al.  The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. , 2009, Neoplasia.

[3]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[4]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[5]  A. Aplin,et al.  B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis , 2006, Oncogene.

[6]  A. Wong,et al.  Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. , 2006, Endocrinology.

[7]  A. Wong,et al.  Activation of p 70 S 6 K Induces Expression of Matrix Metalloproteinase 9 Associated with Hepatocyte Growth Factor-Mediated Invasion in Human Ovarian Cancer Cells , 2006 .

[8]  Ivan Martin,et al.  Three‐dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study , 2005, Journal of cellular physiology.

[9]  L. Mahimainathan,et al.  EGF stimulates mesangial cell mitogenesis via PI3-kinase-mediated MAPK-dependent and AKT kinase-independent manner: involvement of c-fos and p27Kip1. , 2005, American journal of physiology. Renal physiology.

[10]  N. Auersperg,et al.  Gonadotropins Regulate N-cadherin-mediated Human Ovarian Surface Epithelial Cell Survival at Both Post-translational and Transcriptional Levels through a Cyclic AMP/Protein Kinase A Pathway* , 2005, Journal of Biological Chemistry.

[11]  A. Passaniti,et al.  Insulin-like Growth Factor-1 Regulates Endogenous RUNX2 Activity in Endothelial Cells through a Phosphatidylinositol 3-Kinase/ERK-dependent and Akt-independent Signaling Pathway* , 2004, Journal of Biological Chemistry.

[12]  Dianne Miller,et al.  Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. , 2004, Experimental cell research.

[13]  Gong Yang,et al.  Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry , 2004, Cancer Research.

[14]  P. Comoglio,et al.  Hepatocyte Growth Factor Sensitizes Human Ovarian Carcinoma Cell Lines to Paclitaxel and Cisplatin , 2004, Cancer Research.

[15]  D. Radisky,et al.  Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells , 2004, The Journal of cell biology.

[16]  Gong Yang,et al.  Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer , 2003, Oncogene.

[17]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[18]  Toshikazu Nakamura,et al.  NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics , 2003, Cancer science.

[19]  G. Tulunay,et al.  COMPARISON OF HGF (HEPATOCYTE GROWTH FACTOR) LEVELS OF EPITHELIAL OVARIAN CANCER CYST FLUIDS WITH BENIGN OVARIAN CYSTS , 2003, International Journal of Gynecologic Cancer.

[20]  P. Accornero,et al.  K252a inhibits the oncogenic properties of Met, the HGF receptor , 2002, Oncogene.

[21]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[22]  P. Leung,et al.  Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? , 2001, Oncogene.

[23]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Rahimi,et al.  Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  A. N. Corps,et al.  Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells , 1999, International journal of cancer.

[26]  M O Karlsson,et al.  Pharmacokinetic models for the saturable distribution of paclitaxel. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[27]  D. Huntsman,et al.  Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. , 1999, The American journal of pathology.

[28]  J. Downward,et al.  Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor , 1999, Molecular and Cellular Biology.

[29]  R. Gibb,et al.  Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. , 1999, International journal of oncology.

[30]  C. Larabell,et al.  Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. N. Corps,et al.  Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c‐MET , 1997, International journal of cancer.

[32]  R. Kerbel,et al.  Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. , 1997, Cancer research.

[33]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[34]  R. Lefkowitz,et al.  Phosphatidylinositol 3-Kinase Is an Early Intermediate in the Gβγ-mediated Mitogen-activated Protein Kinase Signaling Pathway (*) , 1996, The Journal of Biological Chemistry.

[35]  J. Downward,et al.  Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. , 1996, The EMBO journal.

[36]  W. Fantl,et al.  Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. , 1995, Science.

[37]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[38]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[39]  R. Medema,et al.  Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways , 1993, Molecular and cellular biology.

[40]  T. Nakamura,et al.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor , 1992, Molecular and cellular biology.

[41]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[42]  E. Lapetina,et al.  Association of p21ras with phosphatidylinositol 3-kinase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Folkman,et al.  Role of cell shape in growth control , 1978, Nature.